Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies

被引:53
作者
Bergmann-Leitner, Elke S. [1 ]
Mease, Ryan M. [1 ]
Duncan, Elizabeth H. [1 ]
Khan, Farhat [1 ]
Waitumbi, John [2 ]
Angov, Evelina [1 ]
机构
[1] WRAIR, US Mil Malaria Vaccine Program, Div Malaria Vaccine Dev, Silver Spring, MD 20910 USA
[2] Kenya Govt Med Res Ctr, Walter Reed Project, Kisumu, Kenya
关键词
D O I
10.1186/1475-2875-7-129
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Antibodies are the main effectors against malaria blood-stage parasites. Evaluation of functional activities in immune sera from Phase 2a/b vaccine trials may provide invaluable information in the search for immune correlates of protection. However, the presence of antimalarial-drugs, improper collection/storage conditions or concomitant immune responses against other pathogens can contribute to non-specific anti-parasite activities when the sera/plasma are tested in vitro. Purification of immunoglobulin is a standard approach for reducing such non-specific background activities, but the purification method itself can alter the quality and yield of recovered Ag-specific antibodies. Methods: To address this concern, various immunoglobulin (Ig) purification methods (protein G Sepharose, protein A/G Sepharose, polyethylene glycol and caprylic acid-ammonium sulphate precipitation) were evaluated for their impact on the quality, quantity and functional activity of purified rabbit and human Igs. The recovered Igs were analysed for yield and purity by SDS-PAGE, for quality by Ag-specific ELISAs (determining changes in titer, avidity and isotype distribution) and for functional activity by in vitro parasite growth inhibition assay (GIA). Results: This comparison demonstrated that overall polyethylene glycol purification of human serum/plasma samples and protein G Sepharose purification of rabbit sera are optimal for recovering functional Ag-specific antibodies. Conclusion: Consequently, critical consideration of the purification method is required to avoid selecting non-representative populations of recovered Ig, which could influence interpretations of vaccine efficacy, or affect the search for immune correlates of protection.
引用
收藏
页数:10
相关论文
共 26 条
[1]   Optimisation of aqueous two-phase extraction of human antibodies [J].
Azevedo, Ana M. ;
Rosa, Paula A. J. ;
Ferreira, I. Filipa ;
Aires-Barros, M. Raquel .
JOURNAL OF BIOTECHNOLOGY, 2007, 132 (02) :209-217
[2]   Report:: Miniaturization of a high-throughput pLDH-based Plasmodium falciparum growth inhibition assay for small volume samples from preclinical and clinical vaccine trials [J].
Bergmann-Leitner, Elke S. ;
Duncan, Elizabeth H. ;
Burge, John Robert ;
Spring, Michele ;
Angov, Evelina .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2008, 78 (03) :468-471
[3]   C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria [J].
Bergmann-Leitner, ES ;
Scheiblhofer, S ;
Duncan, EH ;
Leitner, WW ;
Chen, D ;
Angov, E ;
Khan, F ;
Williams, JL ;
Winter, DB ;
Thalhamer, J ;
Lyon, JA ;
Tsokos, GC .
INTERNATIONAL IMMUNOLOGY, 2005, 17 (03) :245-255
[4]  
BJORCK L, 1984, J IMMUNOL, V133, P969
[5]  
Buchacher Andrea, 2006, Biotechnology Journal, V1, P148, DOI 10.1002/biot.200500037
[6]   Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment [J].
Chang, CE ;
Eo, HG ;
Lee, YS ;
Chung, SK ;
Shin, JS ;
Lah, YK ;
Park, CW ;
Jung, JT ;
Huh, JW ;
Lee, SM .
PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, 2000, 30 (03) :177-197
[7]   The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites [J].
Darko, CA ;
Angov, E ;
Collins, WE ;
Bergmann-Leitner, ES ;
Girouard, AS ;
Hitt, SL ;
McBride, JS ;
Diggs, CL ;
Holder, AA ;
Long, CA ;
Barnwell, JW ;
Lyon, JA .
INFECTION AND IMMUNITY, 2005, 73 (01) :287-297
[8]  
ELIASSON M, 1988, J BIOL CHEM, V263, P4323
[9]  
Frank M.B., 2001, MOL BIOL PROTOCOLS
[10]  
INGHAM KC, 1984, METHOD ENZYMOL, V104, P351